Mizuho's Jared Holz talks Novo Nordisk falling on Alzheimer's trial

Here's a comprehensive summary of the YouTube video transcript, maintaining the original language and technical precision:

Key Concepts

• Novo Nordisk (Novo): Pharmaceutical company facing stock decline despite its obesity drug, with investor focus shifting to pipeline development and competition.
• Alzheimer's Drug Trial: A specific trial for Novo Nordisk's Alzheimer's drug that yielded disappointing results, leading to a significant stock drop.
• Obesity Drug Market: A highly competitive market where Novo Nordisk's Wegovy faces strong competition from Eli Lilly's Zepbound.
• Merck: Pharmaceutical company that saw a stock increase due to optimism about its pipeline.
• Bristol Myers Squibb (Bristol): Pharmaceutical company whose stock rose on positive data from a competitor (Bear) with a similar drug mechanism.
• Factor 11 Inhibitors: A class of drugs, including those being developed by Bear and Bristol, targeting conditions like stroke prevention.
• Mega Cap Pharma & Biotech: Large pharmaceutical and biotechnology companies, many of which have performed well in the current year.
• Mergers & Acquisitions (M&A): An active area in the biotech sector, with expectations for continued deal-making in the coming year.
• Valuation Multiples: The price-to-earnings (PE) ratio and other metrics used to assess a company's stock value, with significant disparities noted between companies like Eli Lilly and others.

Novo Nordisk's Stock Performance and Alzheimer's Data

The transcript discusses the significant decline in Novo Nordisk's stock, which has reached 4-5 year lows. This drop is attributed, in part, to disappointing results from its Alzheimer's drug trial. The speaker, Jared Holmes, a healthcare strategist at Mizuho, expresses surprise at the magnitude of the stock's fall, suggesting that the market's reaction was disproportionate to the trial's outcome. Holmes notes that he anticipated a much smaller dip, perhaps around 5%, and that the stock's valuation was not heavily reliant on this specific Alzheimer's drug. He likens Novo Nordisk's situation to "Moderna 2.0," implying that the company may have stagnated at the peak of its success and is now struggling to rebuild its pipeline. The key to Novo Nordisk's recovery, according to Holmes, lies in regaining market share for its obesity drug, Wegovy, against competitors like Eli Lilly's Zepbound.

The Competitive Landscape of Obesity Drugs

A central theme is the intense competition in the obesity drug market. Holmes highlights that Novo Nordisk's obesity drug, Wegovy, has been "second fiddle to Lilly" (referring to Eli Lilly's Zepbound). The market's harsh reaction to Novo Nordisk's performance, even with an obesity drug, suggests that the company might have been better off without it if this was the expected treatment from the street. The expectation is that Novo Nordisk needs to achieve significant share gains in this segment to drive its stock performance.

Performance of Mega Cap Pharma and Biotech Stocks

The discussion shifts to the broader performance of mega-cap pharmaceutical and biotech companies. Jared Holmes points out that it has been an "incredible year for large cap pharma." He cites examples like J&J (up 40%), Eli Lilly (having a "Gangbuster year"), AbbVie (trading at highs), Amgen, and Gilead, all of which have performed exceptionally well year-to-date. While some companies like Merck and Bristol Myers Squibb have not yet reached their year-to-date highs, there is a general "bias to own them." Investors are actively seeking the "driving factor" that will push these stocks to become more positive.

Bristol Myers Squibb and Competitor Data

Bristol Myers Squibb's stock saw a 4% increase, notably on the back of data from Bear (referring to a competitor, likely Bear Stearns or a similar entity in this context, though the transcript is slightly ambiguous here, it's implied to be a company with a similar drug). This rise is significant because Bristol is working on a similar mechanism, Factor 11 inhibitors, for stroke prevention. The positive read-through from Bear's data suggests that if the drug works for Bear, it could also work for Bristol. Holmes emphasizes that when a stock is trading at a low multiple, like Bristol at "seven plus" times earnings, "you don't really need much" to see a stock price increase. This contrasts sharply with the premium valuations, like "two to three standard deviations of multiple," that companies like Eli Lilly command.

Mergers & Acquisitions (M&A) in Biotech

The transcript concludes with a discussion on M&A activity in the biotech sector. Holmes states that the current year has been "incredibly active," with 19 deals north of $500 million in public biotech equity, making it the second-best year in terms of deal volume, though not dollar value compared to years like the Celgene acquisition. Anecdotal evidence and data points strongly suggest that "next year is going to be a huge year, too." The reasoning is that there are still "hundreds of companies that are kind of up for grabs" in the publicly traded biotech space. Holmes mentions a list of "top 40 maybe" companies that span from $30 billion down to $1 billion in market capitalization, indicating a "sweet spot" for potential acquisitions.

Conclusion and Key Takeaways

The pharmaceutical and biotech markets are experiencing significant shifts. Novo Nordisk faces challenges with its pipeline, particularly after a disappointing Alzheimer's trial, and needs to revitalize its obesity drug's market performance. In contrast, mega-cap pharma companies are generally performing well, driven by strong pipelines and market demand. The sector is also witnessing robust M&A activity, with expectations for continued deal-making in the coming year, fueled by a large number of undervalued companies available for acquisition. The disparity in valuation multiples between leading companies like Eli Lilly and others highlights the market's selective nature and the potential for significant upside in companies with strong fundamentals and promising pipelines.